Vishal N Patel1, David C Kaelber2. 1. Center for Clinical Informatics Research and Education, The MetroHealth System, Case Western Reserve University, Cleveland, OH, United States; Center for Proteomics and Bioinformatics, The MetroHealth System, Case Western Reserve University, Cleveland, OH, United States. Electronic address: vishal.patel2@case.edu. 2. Center for Clinical Informatics Research and Education, The MetroHealth System, Case Western Reserve University, Cleveland, OH, United States; Departments of Information Services, The MetroHealth System, Case Western Reserve University, Cleveland, OH, United States; Department of Internal Medicine, The MetroHealth System, Case Western Reserve University, Cleveland, OH, United States; Department of Pediatrics, The MetroHealth System, Case Western Reserve University, Cleveland, OH, United States; Departments of Epidemiology and Biostatistics, The MetroHealth System, Case Western Reserve University, Cleveland, OH, United States.
Abstract
OBJECTIVE: To demonstrate the use of aggregated and de-identified electronic health record (EHR) data for multivariate post-marketing pharmacosurveillance in a case study of azathioprine (AZA). METHODS: Using aggregated, standardized, normalized, and de-identified, population-level data from the Explore platform (Explorys, Inc.) we searched over 10 million individuals, of which 14,580 were prescribed AZA based on RxNorm drug orders. Based on logical observation identifiers names and codes (LOINC) and vital sign data, we examined the following side effects: anemia, cell lysis, fever, hepatotoxicity, hypertension, nephrotoxicity, neutropenia, and neutrophilia. Patients prescribed AZA were compared to patients prescribed one of 11 other anti-rheumatologic drugs to determine the relative risk of side effect pairs. RESULTS: Compared to AZA case report trends, hepatotoxicity (marked by elevated transaminases or elevated bilirubin) did not occur as an isolated event more frequently in patients prescribed AZA than other anti-rheumatic agents. While neutropenia occurred in 24% of patients (RR 1.15, 95% CI 1.07-1.23), neutrophilia was also frequent (45%) and increased in patients prescribed AZA (RR 1.28, 95% CI 1.22-1.34). After constructing a pairwise side effect network, neutropenia had no dependencies. A reduced risk of neutropenia was found in patients with co-existing elevations in total bilirubin or liver transaminases, supporting classic clinical knowledge that agranulocytosis is a largely unpredictable phenomenon. Rounding errors propagated in the statistically de-identified datasets for cohorts as small as 40 patients only contributed marginally to the calculated risk. CONCLUSION: Our work demonstrates that aggregated, standardized, normalized and de-identified population level EHR data can provide both sufficient insight and statistical power to detect potential patterns of medication side effect associations, serving as a multivariate and generalizable approach to post-marketing drug surveillance.
OBJECTIVE: To demonstrate the use of aggregated and de-identified electronic health record (EHR) data for multivariate post-marketing pharmacosurveillance in a case study of azathioprine (AZA). METHODS: Using aggregated, standardized, normalized, and de-identified, population-level data from the Explore platform (Explorys, Inc.) we searched over 10 million individuals, of which 14,580 were prescribed AZA based on RxNorm drug orders. Based on logical observation identifiers names and codes (LOINC) and vital sign data, we examined the following side effects: anemia, cell lysis, fever, hepatotoxicity, hypertension, nephrotoxicity, neutropenia, and neutrophilia. Patients prescribed AZA were compared to patients prescribed one of 11 other anti-rheumatologic drugs to determine the relative risk of side effect pairs. RESULTS: Compared to AZA case report trends, hepatotoxicity (marked by elevated transaminases or elevated bilirubin) did not occur as an isolated event more frequently in patients prescribed AZA than other anti-rheumatic agents. While neutropenia occurred in 24% of patients (RR 1.15, 95% CI 1.07-1.23), neutrophilia was also frequent (45%) and increased in patients prescribed AZA (RR 1.28, 95% CI 1.22-1.34). After constructing a pairwise side effect network, neutropenia had no dependencies. A reduced risk of neutropenia was found in patients with co-existing elevations in total bilirubin or liver transaminases, supporting classic clinical knowledge that agranulocytosis is a largely unpredictable phenomenon. Rounding errors propagated in the statistically de-identified datasets for cohorts as small as 40 patients only contributed marginally to the calculated risk. CONCLUSION: Our work demonstrates that aggregated, standardized, normalized and de-identified population level EHR data can provide both sufficient insight and statistical power to detect potential patterns of medication side effect associations, serving as a multivariate and generalizable approach to post-marketing drug surveillance.
Authors: J F Colombel; N Ferrari; H Debuysere; P Marteau; J P Gendre; B Bonaz; J C Soulé; R Modigliani; Y Touze; P Catala; C Libersa; F Broly Journal: Gastroenterology Date: 2000-06 Impact factor: 22.682
Authors: Clement J McDonald; Stanley M Huff; Jeffrey G Suico; Gilbert Hill; Dennis Leavelle; Raymond Aller; Arden Forrey; Kathy Mercer; Georges DeMoor; John Hook; Warren Williams; James Case; Pat Maloney Journal: Clin Chem Date: 2003-04 Impact factor: 8.327
Authors: Suehyun Lee; Jongsoo Han; Rae Woong Park; Grace Juyun Kim; John Hoon Rim; Jooyoung Cho; Kye Hwa Lee; Jisan Lee; Sujeong Kim; Ju Han Kim Journal: Drug Saf Date: 2019-05 Impact factor: 5.606
Authors: Victoria K Shanmugam; Stephen J Fernandez; Karen Kim Evans; Sean McNish; Anirban N Banerjee; Kara S Couch; Mihriye Mete; Nawar Shara Journal: Wound Repair Regen Date: 2015 Mar-Apr Impact factor: 3.617
Authors: D A Singleton; F Sánchez-Vizcaíno; E Arsevska; S Dawson; P H Jones; P J M Noble; G L Pinchbeck; N J Williams; A D Radford Journal: Prev Vet Med Date: 2018-09-08 Impact factor: 2.670
Authors: Huan Mo; William K Thompson; Luke V Rasmussen; Jennifer A Pacheco; Guoqian Jiang; Richard Kiefer; Qian Zhu; Jie Xu; Enid Montague; David S Carrell; Todd Lingren; Frank D Mentch; Yizhao Ni; Firas H Wehbe; Peggy L Peissig; Gerard Tromp; Eric B Larson; Christopher G Chute; Jyotishman Pathak; Joshua C Denny; Peter Speltz; Abel N Kho; Gail P Jarvik; Cosmin A Bejan; Marc S Williams; Kenneth Borthwick; Terrie E Kitchner; Dan M Roden; Paul A Harris Journal: J Am Med Inform Assoc Date: 2015-09-05 Impact factor: 4.497